Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/1244
Title: | Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice | Authors: | Hosking, D.J. GEUSENS, Piet Rizzoli, R. |
Issue Date: | 2005 | Publisher: | OXFORD UNIV PRESS | Source: | QUARTERLY JOURNAL OF MEDICINE, 98(6). p. 403-413 | Abstract: | A major aim of evidence-based medicine is to assist clinical decision-making by providing the most current and reliable medical information. Systematic reviews and meta-analyses are important tools in this process. Systematic reviews identify and compile relevant evidence, while meta-analyses summarize and quantify the results of such reviews. Results from meta-analyses are, at present, the main source of summary evidence for the efficacy of treatments for a specific condition. They are important tools for helping to choose among treatment options, although they cannot be used to directly compare the magnitude of the effect of various therapies. However, the methods used and the consequent clinical value of the results, may be poorly understood by clinicians, who may therefore not take full advantage of the evidence. Recently, a panel of experts in osteoporosis and evidence-based medicine applied rigorous, validated, scientific standards to produce a systematic review and meta-analysis of randomized controlled trials of anti-resorptive agents used to treat osteoporosis. They found that, although several agents reduced the risk of vertebral fracture, only two, alendronate and risedronate, demonstrated convincing evidence for both non-vertebral and vertebral fracture risk reductions. The clinical implication of these results is that there are important differences in anti-fracture efficacy among currently available agents. In the absence of evidence from head-tohead clinical trials and because of the systematic nature and methodological rigor of the analyses, these data provide important information for clinical decision-making. | Keywords: | HORMONE-REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIAL; BONE-MINERAL DENSITY; ONCE-WEEKLY ALENDRONATE; POSTMENOPAUSAL OSTEOPOROSIS; ANTIRESORPTIVE AGENTS; BIOCHEMICAL MARKERS; RISK REDUCTION; FRACTURE RISK; USERS GUIDES | Document URI: | http://hdl.handle.net/1942/1244 | DOI: | 10.1093/qjmed/hci070 | ISI #: | 000229286800002 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2006 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Osteoporosis.pdf | Peer-reviewed author version | 103.06 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
17
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
15
checked on Sep 25, 2024
Page view(s)
48
checked on Sep 7, 2022
Download(s)
102
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.